Anthem Biosciences Limited has disclosed its schedule for upcoming analyst and institutional investor meets in June 2026. The management will participate in the Nomura Investment Forum Asia 2026 and the Citi India Conference 2026 to engage with investors.

Conference Schedule

The company outlined the specific dates, locations, and meeting formats for the two events. The schedule includes sessions in Singapore and Mumbai, featuring both one-on-one and group meetings.

Disclosure Details

The company stated that no unpublished price-sensitive information (UPSI) will be shared during these meetings. Anthem Biosciences also noted that any unforeseen exigency on the part of the company or the host could lead to changes in the dates or times of the scheduled interactions.

The intimation regarding this participation has been made available on the company's official website.

Anthem Biosciences has reported its financial results for the quarter and year ended March 31, 2026, accompanied by the release of its earnings conference call transcript. The company concluded the fiscal year with a strong performance, posting a profit after tax (PAT) of Rs. 592 crores, a growth of 31% over the previous year. Net profit margins stood at 26% for the full year.

Financial Performance

For the full year FY26, the company achieved a total revenue of Rs. 2,280 crores, an 18% increase compared to the prior year. Consolidated revenue from operations reached Rs. 2,124 crores. The CRDMO business was the primary contributor, generating Rs. 1,773 crores, which represents 83% of the total revenue and reflects an 18% growth. Specialty ingredients contributed Rs. 352 crores.

The fourth quarter of FY26 marked the highest revenue quarter in the company's history. Consolidated revenues for Q4 reached Rs. 611 crores, a year-on-year increase of 26%. The CRDMO segment delivered Rs. 513 crores in revenue for the quarter, growing by 31%, while specialty ingredients recorded Rs. 98 crores. Quarterly PAT stood at Rs. 190 crores, a surge of 130% on a YoY basis with margins of 28.7%.

Operational Highlights and Outlook

Management highlighted that the impact of destocking is largely behind the company, with expectations of restocking driving future growth. The company's EBITDA for the year was Rs. 990 crores, with margins expanding to 43.4%. Looking ahead, the company outlined significant capital expenditure plans focused on expanding its manufacturing capabilities.

The board has approved a major expansion plan for Unit 4, which will be the company's largest project to date. The company plans to invest approximately Rs. 1,200 crores across FY27 and FY28 for Phase 1 of this expansion. This phase is expected to add 365 kiloliters of custom synthesis capacity and 100 kiloliters of fermentation capacity. The capex for the upcoming year is anticipated to be around Rs. 700 crores. Management stated that capacity additions in Unit 2 and Unit 3 provide sufficient headroom until Unit 4 becomes operational.